Authors
Loading...
Targeting PA2G4 leads to significant sensitivity reduction in acute myeloid leukemia cells, indicating a novel therapeutic approach.
Patarino et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: